127 related articles for article (PubMed ID: 28883080)
1. Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.
Voigt AP; Brodersen LE; Alonzo TA; Gerbing RB; Menssen AJ; Wilson ER; Kahwash S; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Wells DA; Loken MR
Haematologica; 2017 Dec; 102(12):2058-2068. PubMed ID: 28883080
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Pardo LM; Voigt AP; Alonzo TA; Wilson ER; Gerbing RB; Paine DJ; Dai F; Menssen AJ; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Wells DA; Brodersen LE; Loken MR
Cytometry B Clin Cytom; 2020 Jan; 98(1):52-56. PubMed ID: 31294507
[TBL] [Abstract][Full Text] [Related]
3. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
[TBL] [Abstract][Full Text] [Related]
4. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
Vujkovic M; Attiyeh EF; Ries RE; Goodman EK; Ding Y; Kavcic M; Alonzo TA; Wang YC; Gerbing RB; Sung L; Hirsch B; Raimondi S; Gamis AS; Meshinchi S; Aplenc R
Blood; 2017 Jun; 129(23):3051-3058. PubMed ID: 28411282
[TBL] [Abstract][Full Text] [Related]
5. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
[TBL] [Abstract][Full Text] [Related]
6. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
Clin Cancer Res; 2015 Jul; 21(14):3187-95. PubMed ID: 25825478
[TBL] [Abstract][Full Text] [Related]
7.
Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
[TBL] [Abstract][Full Text] [Related]
8. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and experimental studies of childhood acute myeloid leukemia with 11q23/MLL rearrangements].
He YX; Xue YQ; Wang HY; Shao XJ; Pan JL; Xu J; Yang NC; Ji ZH; Huang YP; Hu SY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Dec; 29(6):677-82. PubMed ID: 23225048
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group.
Casillas JN; Woods WG; Hunger SP; McGavran L; Alonzo TA; Feig SA;
J Pediatr Hematol Oncol; 2003 Aug; 25(8):594-600. PubMed ID: 12902910
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions.
Cheng J; Klairmont MM; Choi JK
Pediatr Blood Cancer; 2019 Jan; 66(1):e27453. PubMed ID: 30255571
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
[TBL] [Abstract][Full Text] [Related]
16. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
17. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).
Niederwieser C; Nicolet D; Carroll AJ; Kolitz JE; Powell BL; Kohlschmidt J; Stone RM; Byrd JC; Mrózek K; Bloomfield CD
Haematologica; 2016 Dec; 101(12):1516-1523. PubMed ID: 27470602
[TBL] [Abstract][Full Text] [Related]
18. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Ramamurthy R; Hughes M; Morris V; Bolouri H; Gerbing RB; Wang YC; Loken MR; Raimondi SC; Hirsch BA; Gamis AS; Oehler VG; Alonzo TA; Meshinchi S
Pediatr Blood Cancer; 2016 Dec; 63(12):2096-2103. PubMed ID: 27511899
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.
Johnston DL; Alonzo TA; Gerbing RB; Aplenc R; Woods WG; Meshinchi S; Gamis AS
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28453910
[TBL] [Abstract][Full Text] [Related]
20. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
